Intrexon | XON - Selling And Administration Expenses


Intrexon reported $10.31M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Amgen USD 1.58B 354M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 41.74M 4.28M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 20.84M 4.19M Mar/2026
MacroGenics USD 7.94M 1.96M Dec/2025
MannKind USD 54.08M 4.33M Mar/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Veracyte USD 50.84M 7.53M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026